You do not currently have access to this content.
Brian M. Wolpin, Benjamin L. Musher, Gulam A. Manji, Wungki Park, Alexander Spira, Nilofer Azad, Vaia Florou, Tiago Biachi De Castria, Mark H. O'Hara, Erkut Borazanci, Aparna Parikh, John Strickler, ...
AbstractBackground:. DS-8201a is a HER2-targeting antibody drug conjugate with a topoisomerase 1 (topo1) inhibitor payload. Preclinical evidence suggests that inhibiting PARP can potentiate topo1 ...
AbstractBackground:. Computational pathology has successfully incorporated artificial intelligence (AI) methodologies for various applications, including the predictions of therapeutic response, ...
AbstractBackground:. Urothelial carcinoma (UC) affects over 600,000 patients worldwide annually, with the incidence rate increasing over the past decade. Metastatic urothelial carcinoma (mUC) has a ...
DCx Biotherapeutics, Saint-Laurent, Quebec, Canada.
BigHat Biosciences, Inc., San Mateo, CA.
Abstract. PD-L1 is an established immunotherapy target highly expressed in various solid tumors, while B7-H3 is another extensively investigated target overexpressed on a wide range of tumor cells.
Cancer Discov (2026) 16 (4): 670–676.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results